Subtopic Deep Dive
BRAF Mutations in Histiocytic Neoplasms
Research Guide
What is BRAF Mutations in Histiocytic Neoplasms?
BRAF mutations in histiocytic neoplasms refer to recurrent BRAF V600E alterations driving pathogenesis in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman-Destombes disease (RDD), detectable via NGS and IHC.
BRAF V600E occurs in ~50-60% of LCH and ECD cases, with lower prevalence in RDD (Emile et al., 2016, 1505 citations). Studies confirm mutually exclusive BRAF and MAP2K1 mutations activating ERK signaling (Chakraborty et al., 2014, 419 citations). Targeted inhibitors like vemurafenib show sustained efficacy in BRAF-mutant cases (Haroche et al., 2014, 281 citations; Diamond et al., 2017, 392 citations).
Why It Matters
BRAF V600E genotyping guides targeted therapy with vemurafenib or cobimetinib, converting fatal ECD and multisystem LCH into manageable conditions (Diamond et al., 2017; Haroche et al., 2014). In ECD, vemurafenib achieves 100% response rates with durable remission (Goyal et al., 2020, 367 citations). LCH guidelines now mandate BRAF testing for risk-stratified treatment (Haupt et al., 2012, 665 citations). RDD consensus recommends MAPK pathway screening for emerging targeted options (Abla et al., 2018, 581 citations).
Key Research Challenges
Variable BRAF prevalence across entities
BRAF V600E frequency varies: 50-60% in LCH/ECD but <20% in RDD, complicating universal screening (Emile et al., 2016). MAP2K1 mutations fill BRAF-wildtype gaps in LCH (Chakraborty et al., 2014). IHC sensitivity issues demand NGS confirmation (Goyal et al., 2020).
Acquired resistance to BRAF inhibitors
Initial responses to vemurafenib fade due to MAPK reactivation in ECD/LCH (Diamond et al., 2017). Co-occurring CSF1R mutations may contribute to resistance (Durham et al., 2019, 218 citations). MEK combo therapies show promise but require validation (Haroche et al., 2014).
Standardizing mutation detection methods
Discordance between IHC, Sanger, and NGS for BRAF V600E detection persists across histiocytoses (Abla et al., 2018). RDD guidelines stress multi-assay approaches due to emperipolesis masking mutations (Bruce-Brand et al., 2020, 259 citations). Reference standards lacking (Emile et al., 2016).
Essential Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Jean‐François Emile, Oussama Abla, Sylvie Fraitag et al. · 2016 · Blood · 1.5K citations
Abstract The histiocytoses are rare disorders characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults. More t...
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 years
Riccardo Haupt, Milen Minkov, Itziar Astigarraga et al. · 2012 · Pediatric Blood & Cancer · 665 citations
Abstract These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who p...
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Oussama Abla, Eric D. Jacobsen, Jennifer Picarsic et al. · 2018 · Blood · 581 citations
Abstract Rosai-Dorfman-Destombes disease (RDD) is a rare non–Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to ...
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
Rikhia Chakraborty, Oliver Hampton, Xiaoyun Shen et al. · 2014 · Blood · 419 citations
Key Points Recurrent somatic mutations in MAP2K1 were identified in 33% of LCH lesions with wild-type BRAF. The mutant MAPK kinase 1 proteins activate ERK. The ability of MAPK pathway inhibitors to...
Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart et al. · 2017 · JAMA Oncology · 392 citations
In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Gaurav Goyal, Mark Heaney, Matthew Collin et al. · 2020 · Blood · 367 citations
Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mu...
Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF<sup>V600E</sup></i>-Mutated Erdheim-Chester Disease
Julien Haroche, Fleur Cohen‐Aubart, Jean‐François Emile et al. · 2014 · Journal of Clinical Oncology · 281 citations
Purpose Histiocytoses are rare disorders with heterogeneous prognosis. BRAF V600E mutations have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% of pat...
Reading Guide
Foundational Papers
Start with Emile et al. (2016, Blood, 1505 citations) for revised classification linking BRAF to LCH/ECD/R groups; Chakraborty et al. (2014, 419 citations) for mutually exclusive BRAF/MAP2K1 discovery; Haroche et al. (2014, 281 citations) for first vemurafenib proof-of-concept.
Recent Advances
Goyal et al. (2020, 367 citations) for ECD molecular diagnosis/treatment consensus; Abla et al. (2018, 581 citations) for RDD guidelines with BRAF screening; Durham et al. (2019, 218 citations) for CSF1R co-mutations.
Core Methods
NGS panels for MAPK pathway (BRAF V600E, MAP2K1); IHC with VE1 clone; functional ERK phosphorylation assays; targeted sequencing for co-alterations (Chakraborty et al., 2014; Goyal et al., 2020).
How PapersFlow Helps You Research BRAF Mutations in Histiocytic Neoplasms
Discover & Search
Research Agent uses searchPapers('BRAF V600E Langerhans OR Erdheim OR Rosai-Dorfman') to retrieve Emile et al. (2016) as top hit (1505 citations), then citationGraph reveals Diamond et al. (2017) downstream for therapy evidence, while findSimilarPapers on Chakraborty et al. (2014) uncovers MAP2K1 parallels, and exaSearch scans 250M+ OpenAlex papers for unpublished preprints.
Analyze & Verify
Analysis Agent applies readPaperContent on Haroche et al. (2014) to extract vemurafenib response rates (86% ORR), verifyResponse with CoVe cross-checks mutation prevalence against Emile et al. (2016), runPythonAnalysis parses NGS datasets for co-mutation stats (e.g., BRAF+CSF1R), and GRADE grades Diamond et al. (2017) as high-quality evidence for ECD therapy.
Synthesize & Write
Synthesis Agent detects gaps like RDD BRAF-negative therapies via contradiction flagging across Abla et al. (2018) and Goyal et al. (2020), while Writing Agent uses latexEditText for manuscript sections, latexSyncCitations auto-links 10+ histiocytosis papers, latexCompile renders figures, and exportMermaid diagrams BRAF/MEK signaling cascades.
Use Cases
"Extract mutation frequencies from LCH NGS datasets in top papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas parses tables from Chakraborty et al. 2014) → CSV of BRAF 49% vs MAP2K1 33% frequencies with stats.
"Draft LaTeX review on vemurafenib efficacy in BRAF+ ECD"
Synthesis Agent → gap detection on Haroche 2014/Diamond 2017 → Writing Agent → latexEditText + latexSyncCitations + latexCompile → camera-ready PDF with 392-citation efficacy table.
"Find code for histiocytosis MAPK mutation simulators"
Research Agent → paperExtractUrls on Durham 2019 → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python ERK activation models with NumPy simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ BRAF histiocytosis papers) → citationGraph clusters LCH/ECD/RDD → GRADE evidence synthesis → structured report ranking Emile (2016) highest. DeepScan applies 7-step CoVe: readPaperContent(Haroche 2014) → verifyResponse vs Goyal (2020) → runPythonAnalysis survival curves. Theorizer generates hypotheses like 'BRAF/MEK dual blockade overcomes CSF1R co-mutations' from Durham (2019) + Chakraborty (2014).
Frequently Asked Questions
What is the definition of BRAF mutations in histiocytic neoplasms?
Recurrent BRAF V600E mutations drive ~50% of LCH/ECD cases via ERK activation, detected by NGS/IHC (Emile et al., 2016; Chakraborty et al., 2014).
What detection methods are used for BRAF V600E?
IHC for screening, NGS for confirmation; guidelines recommend both due to 10-20% discordance (Goyal et al., 2020; Abla et al., 2018).
What are the key papers on BRAF-targeted therapy?
Haroche et al. (2014, 281 citations) shows vemurafenib 86% response in ECD; Diamond et al. (2017, 392 citations) confirms multi-center efficacy (Emile et al., 2016 classification).
What open problems remain in BRAF histiocytosis research?
Resistance mechanisms to BRAF inhibitors, low RDD prevalence, CSF1R co-mutations need MEK combos (Durham et al., 2019; Chakraborty et al., 2014).
Research Histiocytic Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BRAF Mutations in Histiocytic Neoplasms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers